CN1330640C - 用于治疗异常细胞生长的取代的双环衍生物 - Google Patents

用于治疗异常细胞生长的取代的双环衍生物 Download PDF

Info

Publication number
CN1330640C
CN1330640C CNB2004100696071A CN200410069607A CN1330640C CN 1330640 C CN1330640 C CN 1330640C CN B2004100696071 A CNB2004100696071 A CN B2004100696071A CN 200410069607 A CN200410069607 A CN 200410069607A CN 1330640 C CN1330640 C CN 1330640C
Authority
CN
China
Prior art keywords
methyl
yloxy
phenylamino
pyridin
oxygen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2004100696071A
Other languages
English (en)
Chinese (zh)
Other versions
CN1576275A (zh
Inventor
J·C·卡瑟
S·K·巴塔查尔亚
J·莫里斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
OSI Pharmaceuticals LLC
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CN1576275A publication Critical patent/CN1576275A/zh
Application granted granted Critical
Publication of CN1330640C publication Critical patent/CN1330640C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CNB2004100696071A 2000-06-22 2001-06-14 用于治疗异常细胞生长的取代的双环衍生物 Expired - Fee Related CN1330640C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21313600P 2000-06-22 2000-06-22
US60/213,136 2000-06-22

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN01811470A Division CN1437594A (zh) 2000-06-22 2001-06-14 用于治疗异常细胞生长的取代的双环衍生物

Publications (2)

Publication Number Publication Date
CN1576275A CN1576275A (zh) 2005-02-09
CN1330640C true CN1330640C (zh) 2007-08-08

Family

ID=22793862

Family Applications (3)

Application Number Title Priority Date Filing Date
CNB2004100696071A Expired - Fee Related CN1330640C (zh) 2000-06-22 2001-06-14 用于治疗异常细胞生长的取代的双环衍生物
CNA200810144110XA Pending CN101348467A (zh) 2000-06-22 2001-06-14 用于治疗异常细胞生长的取代的双环衍生物
CN01811470A Pending CN1437594A (zh) 2000-06-22 2001-06-14 用于治疗异常细胞生长的取代的双环衍生物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CNA200810144110XA Pending CN101348467A (zh) 2000-06-22 2001-06-14 用于治疗异常细胞生长的取代的双环衍生物
CN01811470A Pending CN1437594A (zh) 2000-06-22 2001-06-14 用于治疗异常细胞生长的取代的双环衍生物

Country Status (42)

Country Link
US (2) US6890924B2 (OSRAM)
EP (1) EP1292591B1 (OSRAM)
JP (1) JP4044839B2 (OSRAM)
KR (1) KR100545537B1 (OSRAM)
CN (3) CN1330640C (OSRAM)
AP (1) AP2001002192A0 (OSRAM)
AR (1) AR032353A1 (OSRAM)
AT (1) ATE288431T1 (OSRAM)
AU (1) AU2001264159A1 (OSRAM)
BG (1) BG107269A (OSRAM)
BR (1) BR0111548A (OSRAM)
CA (1) CA2413424C (OSRAM)
CZ (1) CZ20023951A3 (OSRAM)
DE (1) DE60108754T2 (OSRAM)
DK (1) DK1292591T3 (OSRAM)
DZ (1) DZ3407A1 (OSRAM)
EA (1) EA005525B1 (OSRAM)
EC (1) ECSP024393A (OSRAM)
EE (1) EE200200710A (OSRAM)
ES (1) ES2236240T3 (OSRAM)
GE (1) GEP20063831B (OSRAM)
HR (1) HRP20021005A2 (OSRAM)
HU (1) HUP0301120A2 (OSRAM)
IL (1) IL152985A0 (OSRAM)
IS (1) IS6616A (OSRAM)
MA (1) MA26914A1 (OSRAM)
MX (1) MXPA02012870A (OSRAM)
MY (1) MY127181A (OSRAM)
NO (1) NO20026166L (OSRAM)
NZ (1) NZ522568A (OSRAM)
OA (1) OA12291A (OSRAM)
PA (1) PA8520301A1 (OSRAM)
PE (1) PE20020257A1 (OSRAM)
PL (1) PL359557A1 (OSRAM)
PT (1) PT1292591E (OSRAM)
SK (1) SK17102002A3 (OSRAM)
SV (1) SV2002000504A (OSRAM)
TN (1) TNSN01091A1 (OSRAM)
UA (1) UA73990C2 (OSRAM)
WO (1) WO2001098277A2 (OSRAM)
YU (1) YU95102A (OSRAM)
ZA (1) ZA200210231B (OSRAM)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772432B2 (en) * 1991-09-19 2010-08-10 Astrazeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors
GB9800569D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
AU761552B2 (en) 1998-10-01 2003-06-05 Astrazeneca Ab Chemical compounds
HUP0301120A2 (hu) * 2000-06-22 2003-08-28 Pfizer Products Inc. Szubsztituált fenilamino-kinazolin-származékok, alkalmazásuk rendellenes sejtnövekedés kezelésére és azokat tartalmazó gyógyszerkészítmények
ATE475652T1 (de) * 2001-02-21 2010-08-15 Mitsubishi Tanabe Pharma Corp Chinazolinderivate
US20030144308A1 (en) * 2001-09-24 2003-07-31 Bauer Paul H. Fructose 1,6-bisphosphatase inhibitors
ES2295409T3 (es) * 2001-11-30 2008-04-16 Osi Pharmaceuticals, Inc. Procedimiento para la preparacion de derivados biciclicos sustituidos para el tratamiento de crecimiento anormal de celulas.
EP1465632A1 (en) * 2001-12-12 2004-10-13 Pfizer Products Inc. Quinazoline derivatives for the treatment of abnormal cell growth
EP1456199A1 (en) * 2001-12-12 2004-09-15 Pfizer Products Inc. Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
CA2491191C (en) 2002-07-15 2014-02-04 Exelixis, Inc. Receptor-type kinase modulators and methods of use
US7488823B2 (en) 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
JP4611745B2 (ja) 2002-11-20 2011-01-12 アレイ バイオファーマ、インコーポレイテッド ＥｒｂＢ２及びＥＧＦＲ阻害剤としてのシアノグアニジン及びシアノアミジン
KR20050085749A (ko) * 2002-12-18 2005-08-29 화이자 프로덕츠 인크. 비정상적 세포 성장의 치료를 위한 4-아닐리노 퀴나졸린유도체
BR0317259A (pt) * 2002-12-19 2005-11-08 Pfizer Prod Inc Complexos de e-2-metóxi-n-(3-{4-[3-metil-4-(6-metilpiridin-3-ilóxi)-fenil amino]- quinazolin-6-il}-alil)-acetamida, seus métodos de produção e utilização
BRPI0409233A (pt) * 2003-04-09 2006-03-28 Pfizer Prod Inc processos para a preparação de derivados de n-((((piridinilóxi)-fenilaminoquinazolinil)-alil) acetamida e compostos relacionados, bem como intermediários de tais processos e processos para a preparação de tais intermediários
JP2007501854A (ja) * 2003-05-27 2007-02-01 ファイザー・プロダクツ・インク 受容体型チロシンキナーゼ阻害薬としてのキナゾリン類およびピリド［３，４−ｄ］ピリミジン類
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
KR101218213B1 (ko) * 2003-07-03 2013-01-04 시토비아 인크. 카스파제의 활성인자 및 세포자멸사의 유도인자로서의4-아릴아미노-퀴나졸린
EP1644017A2 (en) * 2003-07-15 2006-04-12 National Research Council Of Canada Cyclic analogs of human parathyroid hormone for the treatment of conditions characterized by hyperproliferative skin cells
KR100953246B1 (ko) 2003-08-14 2010-04-16 어레이 바이오파마 인크. 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
SG135193A1 (en) * 2003-08-18 2007-09-28 Pfizer Prod Inc Dosing schedule for erbb2 anticancer agents
DK1667991T3 (da) 2003-09-16 2008-08-18 Astrazeneca Ab Quinazolinderivater som tyrosinkinaseinhibitorer
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
CA2744997A1 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and method of use
WO2005044302A1 (en) * 2003-11-06 2005-05-19 Pfizer Products Inc. Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
EP1713781B1 (en) 2004-02-03 2008-11-05 AstraZeneca AB Quinazoline derivatives
US20050192298A1 (en) * 2004-02-27 2005-09-01 Pfizer Inc Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide
JP2008506681A (ja) 2004-07-16 2008-03-06 ファイザー・プロダクツ・インク 抗ｉｇｆ−１ｒ抗体を用いる非血液性の悪性腫瘍の併用療法
CA2577928A1 (en) * 2004-09-01 2006-03-09 Mitsubishi Pharma Corporation Molecular chaperone function regulator
WO2006071079A1 (en) * 2004-12-29 2006-07-06 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof
KR100735639B1 (ko) 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
KR101203328B1 (ko) 2005-04-26 2012-11-20 화이자 인코포레이티드 Ｐ-카드헤린 항체
CA2610491A1 (en) * 2005-06-03 2006-12-07 Pfizer Products Inc. Bicyclic derivatives for the treatment of abnormal cell growth
US20080194596A1 (en) * 2005-06-03 2008-08-14 Frizer Inc. Therapeutic Combination Including a Selective Erbb2 Inhibitor
CN101517068B (zh) 2005-09-07 2017-02-08 安进弗里蒙特公司 活化素受体样激酶‑1的人单克隆抗体
DE602006009968D1 (de) 2005-11-15 2009-12-03 Array Biopharma Inc N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i-rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten
GB0526552D0 (en) * 2005-12-29 2006-02-08 Morvus Technology Ltd New use
EA200802058A1 (ru) 2006-05-09 2009-06-30 Пфайзер Продактс Инк. Производные циклоалкиламинокислот и их фармацевтические композиции
WO2008002039A1 (en) * 2006-06-28 2008-01-03 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting the growth of cancer cell
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
US8604044B2 (en) 2006-09-11 2013-12-10 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
EP2061772A4 (en) * 2006-09-11 2011-06-29 Curis Inc MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
CN101611041A (zh) 2006-12-12 2009-12-23 武田药品工业株式会社 稠合杂环化合物
AU2008212999A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
EP2851091B1 (en) 2007-04-13 2017-12-27 Dana-Farber Cancer Institute, Inc. Methods for treating cancer resistant to ERBB therapeutics
EP2245026B1 (de) 2008-02-07 2012-08-01 Boehringer Ingelheim International GmbH Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
PE20091580A1 (es) 2008-03-12 2009-11-05 Takeda Pharmaceutical Compuesto heterociclico fusionado
US8426430B2 (en) * 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
DK2387563T4 (da) 2009-01-16 2022-07-18 Exelixis Inc Malatsalt af n-(4-{ [ 6, 7-bis(methyloxy)quinolin-4-yl]oxy}phenyl-n'-(4-fluorphenyl)cyclopropan-1,1-dicarboxamid, og krystallinske former deraf til behandling af cancer
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP2473500A2 (en) 2009-09-01 2012-07-11 Pfizer Inc. Benzimidazole derivatives
WO2011153049A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
WO2011153050A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
WO2012052948A1 (en) 2010-10-20 2012-04-26 Pfizer Inc. Pyridine- 2- derivatives as smoothened receptor modulators
KR20140059246A (ko) 2011-09-22 2014-05-15 화이자 인코포레이티드 피롤로피리미딘 및 퓨린 유도체
CN102872018B (zh) * 2012-10-23 2015-07-15 广州市恒诺康医药科技有限公司 酪氨酸激酶不可逆抑制剂及其制备方法和用途
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
WO2015155624A1 (en) 2014-04-10 2015-10-15 Pfizer Inc. Dihydropyrrolopyrimidine derivatives
EA033919B1 (ru) 2014-04-30 2019-12-10 Пфайзер Инк. Соединённые циклоалкилом дигетероциклические производные
KR101589632B1 (ko) 2014-06-03 2016-02-01 한국과학기술연구원 항암활성을 가지는 6-벤질옥시퀴나졸린-7-일유레아 유도체
WO2016001789A1 (en) 2014-06-30 2016-01-07 Pfizer Inc. Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
US10287401B2 (en) 2015-07-01 2019-05-14 California Institute Of Technology Cationic mucic acid polymer-based delivery systems
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
WO2017148391A1 (zh) * 2016-03-01 2017-09-08 上海医药集团股份有限公司 一种含氮杂环化合物、制备方法、中间体、组合物和应用
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
WO2019241327A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles for crossing the blood brain barrier and methods of treatment using the same
HUE069764T2 (hu) 2018-09-18 2025-04-28 Hoffmann La Roche Kinazolin-származékok, mint daganatellenes szerek
WO2023185793A1 (zh) * 2022-03-28 2023-10-05 江苏恒瑞医药股份有限公司 含氮杂环类化合物、其制备方法及其在医药上的应用
WO2025067396A1 (zh) * 2023-09-27 2025-04-03 江苏恒瑞医药股份有限公司 一种喹唑啉衍生物的可药用盐、其结晶形式及用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821246A (en) * 1994-11-12 1998-10-13 Zeneca Limited Aniline derivatives
CN1211240A (zh) * 1996-02-14 1999-03-17 曾尼卡有限公司 作为抗肿瘤剂的喹唑啉衍生物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
DE69925141T2 (de) 1998-10-08 2006-04-27 Astrazeneca Ab Chinazolin derivate
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
HUP0301120A2 (hu) * 2000-06-22 2003-08-28 Pfizer Products Inc. Szubsztituált fenilamino-kinazolin-származékok, alkalmazásuk rendellenes sejtnövekedés kezelésére és azokat tartalmazó gyógyszerkészítmények

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821246A (en) * 1994-11-12 1998-10-13 Zeneca Limited Aniline derivatives
CN1211240A (zh) * 1996-02-14 1999-03-17 曾尼卡有限公司 作为抗肿瘤剂的喹唑啉衍生物

Also Published As

Publication number Publication date
MXPA02012870A (es) 2003-05-14
CN1437594A (zh) 2003-08-20
CZ20023951A3 (cs) 2004-01-14
ATE288431T1 (de) 2005-02-15
IS6616A (is) 2002-11-14
CN101348467A (zh) 2009-01-21
NZ522568A (en) 2004-12-24
AP2001002192A0 (en) 2002-12-21
MY127181A (en) 2006-11-30
DE60108754T2 (de) 2005-06-23
DZ3407A1 (OSRAM) 2001-12-27
MA26914A1 (fr) 2004-12-20
KR20030016303A (ko) 2003-02-26
SV2002000504A (es) 2002-10-24
EE200200710A (et) 2004-06-15
NO20026166D0 (no) 2002-12-20
BR0111548A (pt) 2003-05-06
US20050159435A1 (en) 2005-07-21
EA005525B1 (ru) 2005-04-28
AU2001264159A1 (en) 2002-01-02
GEP20063831B (en) 2006-05-25
CN1576275A (zh) 2005-02-09
US6890924B2 (en) 2005-05-10
OA12291A (en) 2004-03-18
JP4044839B2 (ja) 2008-02-06
PE20020257A1 (es) 2002-04-08
HK1069576A1 (en) 2005-05-27
UA73990C2 (en) 2005-10-17
US7332493B2 (en) 2008-02-19
AR032353A1 (es) 2003-11-05
CA2413424C (en) 2007-10-02
WO2001098277A3 (en) 2002-06-13
KR100545537B1 (ko) 2006-01-25
BG107269A (bg) 2003-06-30
US20020169165A1 (en) 2002-11-14
ES2236240T3 (es) 2005-07-16
JP2004501139A (ja) 2004-01-15
YU95102A (sh) 2005-11-28
EP1292591B1 (en) 2005-02-02
HUP0301120A2 (hu) 2003-08-28
DE60108754D1 (de) 2005-03-10
ECSP024393A (es) 2003-02-06
EP1292591A2 (en) 2003-03-19
HRP20021005A2 (en) 2004-02-29
PL359557A1 (en) 2004-08-23
CA2413424A1 (en) 2001-12-27
PA8520301A1 (es) 2003-06-30
PT1292591E (pt) 2005-06-30
ZA200210231B (en) 2004-02-12
DK1292591T3 (da) 2005-05-30
TNSN01091A1 (fr) 2005-11-10
SK17102002A3 (sk) 2004-04-06
WO2001098277A2 (en) 2001-12-27
IL152985A0 (en) 2003-06-24
NO20026166L (no) 2002-12-20
EA200201277A1 (ru) 2003-06-26

Similar Documents

Publication Publication Date Title
CN1330640C (zh) 用于治疗异常细胞生长的取代的双环衍生物
US7585869B2 (en) Substituted heterocylces for the treatment of abnormal cell growth
JP4181502B2 (ja) 異常な細胞増殖を治療するためのキナゾリン誘導体
US20050101618A1 (en) Selective erbB2 inhibitor/anti-erbB antibody combinations in the treatment of cancer
NO322297B1 (no) Substituerte bisycliske derivater, anvendelse derav samt farmasoytisk sammensetning.
US20080194596A1 (en) Therapeutic Combination Including a Selective Erbb2 Inhibitor
EP1249451B1 (en) Bicyclic-substituted 4-amino-pyridopyrimidine derivatives
HK1069576B (en) Substituted bicyclic derivatives for the treatment of abnormal cell growth
HK1071293A (en) Quinazoline derivatives for the treatment of abnormal cell growth

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1069576

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: AGOURON PHARMA

Free format text: FORMER OWNER: PFIZER PRODUCTS INC.

Effective date: 20090612

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20090612

Address after: New York, United States

Co-patentee after: Osi Pharm Inc.

Patentee after: Pfizer

Address before: American Connecticut

Patentee before: Pfizer Products Inc.

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070808

Termination date: 20110614